Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

Wedbush keeps Climb Bio (CLYM) as a top pick with a $25 target, citing strong clinical data and catalysts through 2027. The stock fell 14% after recent updates, but the firm sees misplaced investor concerns and highlights positive Phase 1 results for CLYM116, including a 33-day half-life and significant reductions in Gd-IgA1 and free APRIL.

Piper Sandler reiterated an Overweight rating and $40 price target for Climb Bio (CLYM) after data presentations at the American Society of Nephrology meeting. The firm highlighted positive Phase 1 data for CLYM116 and budoprutug, with key Phase 2 and 3 milestones expected in 2027. CLYM stock has fallen 18% in a week to $9.21, despite a 319% gain over the past year. Analysts maintain strong buy consensus with price targets ranging from $18 to $35.

Guggenheim reiterated a Buy rating and $35.00 price target for Climb Bio (CLYM) after positive data on its kidney drug candidates. The stock, up 400% in a year, trades at $10.19. Analysts highlight strong Phase III data for budoprutug and promising CLYM116 results. Multiple firms raised price targets, citing potential in autoimmune disease treatments.

Climb Bio reported Phase 2 data for budoprutug, showing a 70% mean reduction in PLA2R antibodies at Week 12. 38% of patients in the 200 mg cohort achieved immunologic remission. The 600 mg cohort showed 98% B-cell suppression at Week 4. The drug was well tolerated with no serious events. Additional data is expected in 2027, according to the company.

Climb Bio (CLYM) presented Phase 2 trial data for budoprutug, an anti-CD19 antibody, showing B-cell depletion and PLA2R antibody reductions in kidney disease patients. The 200 mg dose achieved 70% mean antibody reduction, with 5/13 patients in remission. The 600 mg dose showed deeper B-cell depletion. The drug was well-tolerated. Climb Bio expects more data in 2027. Primary membranous nephropathy affects 75,000 people in the U.S. without FDA-approved treatments.

Climb Bio (CLYM) reported early Phase 2 data for budoprutug in pMN, showing B-cell depletion, antibody reduction, and immunologic remission at 12 weeks. Both 200 mg and 600 mg doses were generally well tolerated. The company expects further data in 2027.